ArticleOncoTargets and therapy2021

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report.

Yuanyang Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.